Home » Newsletters » BioWorld Science

BioWorld Science

May 31, 2016

View Archived Issues

FDA grants orphan drug designation to RT-001 for Friedreich's ataxia

Androgen receptor splice variants linked to castration resistance in prostate cancer

Immunotherapy with 3BNC117 elicits host immune responses against HIV-1

Immune responses to peptide vaccine encoding mutated IDH1 gene seen in glioma patients

CareDx completes enrollment in DART study of AlloSure

Bristol-Myers Squibb patents HIV maturation inhibitors

Pre Diagnostics and Bioventix collaborate on blood-based Alzheimer's diagnostic test

Roche discloses vasopressin V1A receptor antagonists

Immatics describes multi-peptide hepatocellular carcinoma vaccine entering clinical study

European launch of Darzalex triggers milestone payment to Genmab

VIB, UGhent and UA present ferroptosis inhibitors

Genentech and Constellation Pharmaceuticals describe bromodomain inhibitors

Briviact now available in U.S. for epilepsy patients with partial-onset seizures

Nanobiotix reports preclinical proof-of-concept data on NBTXR-3 in immuno-oncology

European approval for subcutaneous MabThera in CLL

Pixium cleared to begin trial of IRIS II bionic vision system in U.K.

Stempeucel allogeneic cell therapy receives limited approval in India

Collaboration to develop a novel atopy patch-test diagnostic for cow's milk allergy

Simponi receives positive opinion in Europe for treatment of pJIA

Ixaltis successfully completes its first fundraising round

European Commission grants marketing approval for the anti-TNF-alpha biosimilar Flixabi

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...